GlassScriptPhysician profile
Dana R Williams
NPI 1891839478
$1,454.15
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,112 · 2022: $342.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.06 | 2021-2022 | |
| Amgen INC. | $194.05 | 2021-2022 | |
| Abbvie INC. | $191.65 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $183.89 | 2021 | |
| Lilly USA, LLC | $163.92 | 2021-2022 | |
| Astellas Pharma US INC | $126.31 | 2021-2022 | |
| Organogenesis INC. | $73.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $56.60 | 2022 | |
| Pfizer INC. | $26.48 | 2021 | |
| Apria Healthcare LLC | $23.68 | 2021 | |
| Genentech USA, INC. | $21.30 | 2021 | |
| Esperion Therapeutics, INC. | $19.54 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.00 | 2021 | |
| Tactile Systems Technology INC | $17.38 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.37 | 2021 | |
| Convatec INC. | $14.98 | 2021 | |
| Amarin Pharma, INC. | $14.13 | 2021 | |
| Mylan Specialty L.P. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.